Browse the evidence

Adherence to a Mediterranean diet (MedDiet) is associated with reduced body weight, lower BMI, and a decreased risk of incident overweight or obesity compared to control diets or low-adherence groups.

Adopt a Mediterranean-style eating pattern as your default. Focus on daily consumption of vegetables, fruits, whole grains, legumes, nuts, and olive oil. Eat fish 2-3 times a week and limit red/processed meats and sweets. You do not need to count calories strictly, but prioritize whole, minimally processed foods. This approach is sustainable, tasty, and has strong evidence for preventing weight gain and obesity.

GLP-1 receptor agonists (specifically semaglutide 2.4 mg weekly and liraglutide 3.0 mg daily) produce significant weight loss in adults with obesity without diabetes, with semaglutide demonstrating superior efficacy compared to liraglutide.

For adults with obesity without diabetes, GLP-1 receptor agonists like semaglutide (2.4 mg weekly) and liraglutide (3.0 mg daily) are effective weight loss treatments. Semaglutide offers greater weight reduction than liraglutide. These drugs work by mimicking a hormone that increases satiety and slows digestion. Common side effects include gastrointestinal issues, which are often managed by starting with a lower dose and gradually increasing it.

GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide and liraglutide produce significant, sustained weight reduction in adults with obesity by acting on the gut-brain axis to reduce appetite and food intake.

Semaglutide 2.4 mg injected once weekly, combined with lifestyle counseling, leads to an average 14.9% body weight loss in adults with obesity over 68 weeks. Side effects like nausea are common initially but typically subside; starting with a lower dose helps manage this.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces greater weight reduction than GLP-1 monotherapy in individuals with obesity without type 2 diabetes.

Tirzepatide 15 mg injected once weekly leads to an average 20.9% body weight loss in adults with obesity without diabetes over 72 weeks. This dual-action hormone therapy is more effective than GLP-1 monotherapy.

Adherence to a diet high in fruit, vegetables, nuts, legumes, fish, and whole-fat dairy is associated with significantly lower all-cause mortality and cardiovascular disease risk across diverse global populations, particularly in lower-income countries.

Focus your daily diet on increasing the intake of six specific food groups: fruits, vegetables, legumes, nuts, fish, and whole-fat dairy. Aim to consume these foods in amounts that exceed the median intake of your local population. This pattern is associated with a 30% lower risk of death and an 18% lower risk of cardiovascular events. This is particularly impactful in lower-income regions where these foods are less commonly consumed.

Mediterranean, DASH-style, pescetarian, and ovo/lacto-vegetarian dietary patterns, when implemented as intended, strongly align with 2021 AHA Dietary Guidance and support optimal cardiovascular health.

Adopt a Mediterranean, DASH, pescetarian, or vegetarian diet as your primary way of eating. Focus on vegetables, fruits, whole grains, and healthy fats like olive oil. If you eat animal products, choose lean meats, fish, or low-fat dairy. This approach is flexible, culturally adaptable, and strongly supported by heart health guidelines.

Second-generation anti-obesity medications (semaglutide 2.4 mg and tirzepatide) induce significantly greater weight loss (15-21%) compared to traditional lifestyle modification (5-10%) by pharmacologically enhancing satiation and reducing hunger, thereby decreasing the reliance on cognitive behavioral strategies for calorie restriction.

If you have obesity, second-generation medications like semaglutide or tirzepatide are significantly more effective than lifestyle changes alone, producing 15-21% weight loss compared to 5-10%. They work by reducing hunger and increasing fullness, which reduces the mental effort needed to restrict calories. While they require weekly injections and gradual dose titration to manage side effects, they represent a major advancement in obesity treatment.

Tirzepatide, a dual GIP/GLP-1 receptor agonist administered via once-weekly subcutaneous injections, significantly improves glycemic control and reduces body weight in patients with type 2 diabetes and obesity compared to placebo, GLP-1 agonists, and basal insulin.

Tirzepatide is a once-weekly injection that activates two gut hormones (GIP and GLP-1) to help your pancreas release insulin when needed, slow down digestion, and reduce appetite. It is prescribed for type 2 diabetes and obesity. Clinical trials show it lowers blood sugar and body weight more effectively than many existing diabetes and weight-loss medications. Common side effects include nausea and diarrhea, which usually improve over time. It is taken alongside diet and exercise changes.

GLP-1 Receptor Agonists (GLP-1 RA) and SGLT-2 Inhibitors (SGLT-2i) provide significant cardiovascular and renal benefits, with GLP-1 RAs also offering substantial weight loss and HbA1c reduction.

Consider GLP-1 RAs or SGLT-2 inhibitors if you need better blood sugar control, weight loss, or heart protection. These drugs have strong evidence for reducing heart attacks and strokes. Be aware of potential stomach issues, which often improve over time.

Sustained weight loss of 5-10% or greater through negative energy balance interventions (behavioral, pharmacological, or surgical) prevents, reduces, or resolves obesity-related complications such as type 2 diabetes, hypertension, and fatty liver disease.

To significantly lower your risk of type 2 diabetes and other obesity-related diseases, you need to achieve and maintain a weight loss of at least 5-10% of your body weight. This can be done through lifestyle changes, medications, or surgery. The key is that the weight loss must be sustained over the long term, not just short-term dieting.

Greater magnitude of weight loss (e.g., >10-15%) is required to achieve remission of type 2 diabetes, whereas moderate weight loss (5-10%) is sufficient for prevention or delay.

If you want to prevent type 2 diabetes, losing 5-10% of your body weight is a great start. However, if you already have type 2 diabetes and want to achieve remission, you likely need to lose more than 10-15% of your body weight and keep it off.

Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) produce significantly greater body weight loss and higher rates of prediabetes-to-normoglycemia conversion compared to GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and placebo in non-diabetic obese individuals.

If you have obesity or are overweight without diabetes, a once-weekly dual-acting injection (tirzepatide) can lead to significant weight loss (up to 21% in trials) and often reverses prediabetes. This is more effective than older GLP-1 drugs. It requires lifestyle changes alongside the medication.

GLP-1 receptor agonists (semaglutide, liraglutide, exenatide) significantly reduce body weight and improve glucose metabolism in non-diabetic obese individuals and those with prediabetes, often leading to normoglycemia.

For non-diabetic individuals with obesity or prediabetes, weekly GLP-1 injections (semaglutide 2.4 mg) can lead to significant weight loss (approx. 15%) and high rates of returning to normal blood sugar levels. This is more effective than lifestyle changes alone.

Adherence to a Mediterranean dietary pattern significantly reduces the risk of major cardiovascular events, all-cause mortality, and coronary heart disease mortality in both primary and secondary prevention populations.

Adopt a Mediterranean-style eating pattern as your default. Fill your plate with vegetables, fruits, legumes, nuts, and whole grains. Use extra virgin olive oil as your primary fat source and eat fatty fish regularly. Limit red meat, sweets, and processed foods. This pattern is proven to significantly lower your risk of heart attack, stroke, and death.

Replacing saturated fatty acids (SFA) with polyunsaturated fatty acids (PUFA) or monounsaturated fatty acids (MUFA) results in the greatest reduction in LDL cholesterol and apoB, whereas replacing SFA with carbohydrates yields only modest apoB lowering.

To lower your LDL cholesterol, replace saturated fats (found in red meat, full-fat dairy, and tropical oils) with unsaturated fats. Prioritize polyunsaturated fats (found in fatty fish, walnuts, and vegetable oils) and monounsaturated fats (found in olive oil and avocados). Avoid replacing these fats with refined carbohydrates like white bread or sugar, as this is less effective for lowering cholesterol.

Adherence to a DASH dietary pattern significantly lowers systolic and diastolic blood pressure, with greater effects observed in hypertensive individuals, and this effect is amplified by low sodium intake.

Follow the DASH diet: eat plenty of vegetables, fruits, whole grains, and low-fat dairy, while limiting red meat, saturated fat, and sugar. To maximize blood pressure benefits, also reduce your sodium intake. This combination is highly effective for lowering blood pressure, especially if you have hypertension.

Discontinuation of GLP-1 therapy leads to significant weight regain (up to two-thirds of lost weight within 1 year), highlighting the necessity of long-term lifestyle interventions and potentially long-term medication use.

Understand that GLP-1 therapy is likely a long-term treatment for obesity. If you stop the medication, you will likely regain a significant portion of your lost weight. Work with your provider to determine if you should stay on the medication long-term or transition to a maintenance strategy that includes intensive lifestyle support.

Discontinuation of anti-obesity medications (AOMs) after weight loss leads to significant weight regain (approx. two-thirds of lost weight) and reversal of cardiometabolic improvements, necessitating long-term treatment.

Obesity is a chronic condition. If you stop taking your medication after losing weight, you will likely regain most of that weight (about two-thirds) and lose the health benefits. Treatment should be viewed as long-term management, similar to blood pressure medication, rather than a short-term fix.

SGLT2 inhibitors are preferred over GLP1RAs for adults with type 2 diabetes and heart failure to reduce major adverse cardiovascular events and worsening heart failure, while GLP1RAs are preferred for chronic kidney disease if SGLT2is are not tolerated.

If you have type 2 diabetes and heart failure, ask about SGLT2 inhibitors (like empagliflozin or dapagliflozin), as they are proven to help your heart. If you have kidney disease, SGLT2 inhibitors are also preferred, but if you can't take them, GLP-1 agonists (like dulaglutide) are a good alternative for protecting your kidneys. Your doctor will choose based on your specific organ risks.

Metformin produces moderate weight loss (3-5% reduction) in adults with T2DM or obesity, primarily by lowering hunger and reducing calorie intake, and can prevent weight gain associated with antipsychotic medications.

Metformin is a cornerstone treatment for Type 2 Diabetes that also offers moderate weight loss benefits (typically 3-5% body weight reduction). It works by reducing appetite and calorie intake. It is particularly useful for patients who need to counteract weight gain caused by other medications, such as antipsychotics. While gastrointestinal side effects are common, they often subside, and the long-term weight and metabolic benefits are substantial.

GLP-1 receptor agonists improve glycemic control, promote significant weight loss, and reduce cardiovascular events in patients with type 2 diabetes.

If you have type 2 diabetes and heart risks, GLP-1 injections can help lower blood sugar, lose weight, and protect your heart.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, provides superior glycemic control and greater weight loss compared to GLP-1 receptor agonists.

Tirzepatide is a newer injection that works on two hormones to lower blood sugar and lose more weight than older GLP-1 drugs.

Bariatric surgery patients have extremely high rates of pre-existing micronutrient deficiencies, requiring comprehensive screening and aggressive post-operative supplementation.

If you are having bariatric surgery, get screened for nutrient deficiencies beforehand. Do not rely on standard multivitamins alone; you will likely need specific, higher-dose supplements tailored to your blood work to prevent long-term health issues.

GLP-1 receptor agonists improve glycemic control and promote weight loss in type 2 diabetes and obesity by stimulating glucose-dependent insulin secretion and reducing appetite, with efficacy superior to many existing therapies.

GLP-1 receptor agonists are highly effective treatments for Type 2 Diabetes and Obesity. They work by mimicking a natural hormone to increase insulin when blood sugar is high and reducing appetite. While they are usually given by injection (some are oral), they offer significant benefits in lowering blood sugar and losing weight, often more so than older diabetes medications. Common side effects like nausea are frequent but often improve over time. These drugs are not suitable for everyone, particularly those with a history of certain thyroid cancers or pancreatitis.